ArQule’s lead drug tivantinib flops again in PhIII liver cancer study
ArQule and Daiichi Sankyo’s tivantinib has come up short in another Phase III study.
Five years after the biotech’s lead drug flopped in a late-stage study for non-small cell lung cancer, investigators said that the same fate befell its Phase III for hepatocellular carcinoma, a common form of primary liver cancer. The drug flunked the primary endpoint on overall survival.
The drug also failed a Phase II in colorectal cancer in 2013.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.